patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_191655 | REC_0007501 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.7 | 61 | female | 1 | 34 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:58.691851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871241 | REC_0007502 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 34 | 14.5 | 59 | female | 0 | 5 | 4.4 | 0 | entrectinib 600 mg daily | 28.7 | true | MSI-H | 2026-03-15T05:35:58.692203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139239 | REC_0007503 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.3 | 74 | female | 1 | 8 | 4.3 | 7 | sotorasib 960 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:58.692455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833262 | REC_0007504 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 7.5 | 66 | male | 0 | 30 | 4 | 1 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:35:58.692693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524028 | REC_0007505 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 8.4 | 79 | female | 2 | 30 | 3.5 | 2 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:58.692925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738485 | REC_0007506 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 14.7 | 74 | female | 1 | 18 | 5.6 | 1 | osimertinib 80 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:35:58.693164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785769 | REC_0007507 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 3.5 | 69 | female | 0 | 49 | 6.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 18.4 | true | MSS | 2026-03-15T05:35:58.693399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764695 | REC_0007508 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 10.5 | 56 | male | 1 | 24 | 5.4 | 3 | entrectinib 600 mg daily | 15.4 | false | MSS | 2026-03-15T05:35:58.693635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137747 | REC_0007509 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.7 | 65 | female | 0 | 45 | 4.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 12 | false | MSS | 2026-03-15T05:35:58.693869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459546 | REC_0007510 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 8.2 | 77 | female | 1 | 75 | 3.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.2 | true | MSS | 2026-03-15T05:35:58.694098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123701 | REC_0007511 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 38 | 8 | 62 | female | 0 | 51 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.1 | true | MSS | 2026-03-15T05:35:58.694334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827209 | REC_0007512 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 9.7 | 61 | female | 1 | 4 | 3.8 | 6 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:58.694567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129451 | REC_0007513 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 7.8 | 66 | female | 1 | 13 | 4.7 | 6 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:58.694797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552462 | REC_0007514 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6 | 58 | male | 1 | 28 | 6.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:35:58.695030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318458 | REC_0007515 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 13.4 | 64 | male | 1 | 19 | 4.1 | 6 | alectinib 600 mg BID | 14.9 | false | MSI-H | 2026-03-15T05:35:58.695345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429167 | REC_0007516 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.8 | 62 | female | 1 | 0 | 5.3 | 6 | osimertinib 80 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:58.695582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131856 | REC_0007517 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 15.5 | 69 | male | 1 | 19 | 6.3 | 6 | osimertinib 80 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:58.695819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890878 | REC_0007518 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 14.4 | 61 | male | 0 | 10 | 6.6 | 5 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:58.696054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480767 | REC_0007519 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 13 | 71 | female | 2 | 7 | 4.1 | 5 | entrectinib 600 mg daily | 15.5 | true | MSI-H | 2026-03-15T05:35:58.696413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955546 | REC_0007520 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 10 | 56 | male | 0 | 14 | 3.7 | 3 | osimertinib 80 mg daily | 11.3 | true | MSS | 2026-03-15T05:35:58.696656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796049 | REC_0007521 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 14.1 | 60 | female | 1 | 16 | 5.6 | 5 | sotorasib 960 mg daily | 9.7 | true | MSI-H | 2026-03-15T05:35:58.696892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417631 | REC_0007522 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 12.4 | 65 | female | 0 | 14 | 8.4 | 2 | osimertinib 80 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:58.697127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114022 | REC_0007523 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 11 | 75 | male | 0 | 19 | 5 | 2 | pembrolizumab 200 mg q3w | 16.4 | false | MSS | 2026-03-15T05:35:58.697364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153107 | REC_0007524 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.6 | 57 | male | 1 | 30 | 3.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 20.4 | false | MSS | 2026-03-15T05:35:58.697595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848595 | REC_0007525 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 2.7 | 67 | female | 0 | 49 | 4.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.3 | true | MSS | 2026-03-15T05:35:58.697828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288071 | REC_0007526 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 16 | 64 | female | 1 | 4 | 5.5 | 0 | sotorasib 960 mg daily | 37.4 | false | MSI-H | 2026-03-15T05:35:58.698066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502609 | REC_0007527 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 9.4 | 67 | female | 1 | 18 | 6.2 | 5 | sotorasib 960 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:58.698296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584491 | REC_0007528 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 6.1 | 59 | female | 1 | 2 | 5.1 | 6 | sotorasib 960 mg daily | 11.3 | true | MSS | 2026-03-15T05:35:58.698583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937133 | REC_0007529 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 4.6 | 49 | female | 0 | 6 | 5.2 | 6 | osimertinib 80 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:58.698819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800198 | REC_0007530 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 14.1 | 77 | female | 2 | 14 | 5.3 | 6 | alectinib 600 mg BID | 6.3 | false | MSI-H | 2026-03-15T05:35:58.699050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540752 | REC_0007531 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 15 | 63 | male | 0 | 20 | 4.8 | 5 | sotorasib 960 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:58.699288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549535 | REC_0007532 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.2 | 76 | female | 1 | 11 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.5 | true | MSS | 2026-03-15T05:35:58.699514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376572 | REC_0007533 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 5.8 | 83 | female | 2 | 13 | 5.8 | 4 | osimertinib 80 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:58.699746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203024 | REC_0007534 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 8.7 | 69 | female | 0 | 19 | 5.5 | 7 | alectinib 600 mg BID | 10.4 | false | MSS | 2026-03-15T05:35:58.699976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495143 | REC_0007535 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 12.8 | 81 | male | 2 | 17 | 5.3 | 2 | osimertinib 80 mg daily | 16.4 | false | MSI-H | 2026-03-15T05:35:58.700287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170832 | REC_0007536 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 7 | 63 | male | 0 | 19 | 4.8 | 8 | entrectinib 600 mg daily | 7.5 | false | MSS | 2026-03-15T05:35:58.700526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987480 | REC_0007537 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.4 | 73 | female | 2 | 34 | 5.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.7 | true | MSS | 2026-03-15T05:35:58.700766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553161 | REC_0007538 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 12.6 | 72 | female | 2 | 18 | 5 | 2 | osimertinib 80 mg daily | 15.1 | true | MSS | 2026-03-15T05:35:58.701010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209853 | REC_0007539 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 17.1 | 64 | male | 0 | 11 | 6.6 | 1 | entrectinib 600 mg daily | 26.3 | false | MSI-H | 2026-03-15T05:35:58.701250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832459 | REC_0007540 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.3 | 65 | female | 1 | 18 | 7.6 | 6 | alectinib 600 mg BID | 17.7 | true | MSI-H | 2026-03-15T05:35:58.701484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790951 | REC_0007541 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 18.2 | 66 | female | 0 | 11 | 6 | 4 | osimertinib 80 mg daily | 8.4 | true | MSS | 2026-03-15T05:35:58.701766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701039 | REC_0007542 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 8.3 | 63 | male | 0 | 15 | 7.6 | 3 | entrectinib 600 mg daily | 15 | true | MSS | 2026-03-15T05:35:58.702002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178744 | REC_0007543 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 7.5 | 90 | male | 2 | 36 | 5.6 | 5 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:35:58.702236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660698 | REC_0007544 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.8 | 75 | female | 2 | 17 | 5.4 | 7 | osimertinib 80 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:58.702468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600601 | REC_0007545 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 8.1 | 68 | female | 1 | 36 | 5.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 13 | true | MSS | 2026-03-15T05:35:58.702697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849610 | REC_0007546 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 36 | 16.8 | 74 | female | 2 | 28 | 5.5 | 6 | sotorasib 960 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:58.702927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731158 | REC_0007547 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.6 | 69 | female | 0 | 54 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.5 | true | MSS | 2026-03-15T05:35:58.703155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641900 | REC_0007548 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.5 | 69 | female | 0 | 7 | 5.8 | 6 | osimertinib 80 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:35:58.703390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716721 | REC_0007549 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 7.1 | 54 | male | 0 | 20 | 7.2 | 0 | pembrolizumab 200 mg q3w | 18.4 | false | MSS | 2026-03-15T05:35:58.703621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395880 | REC_0007550 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 6.3 | 64 | male | 0 | 55 | 5.2 | 5 | pembrolizumab 200 mg q3w | 23.6 | true | MSS | 2026-03-15T05:35:58.703856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600082 | REC_0007551 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 12.3 | 77 | male | 0 | 17 | 5.1 | 5 | entrectinib 600 mg daily | 5.9 | true | MSS | 2026-03-15T05:35:58.704121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117510 | REC_0007552 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 32 | 12.4 | 72 | female | 2 | 8 | 4.7 | 0 | sotorasib 960 mg daily | 28.7 | true | MSS | 2026-03-15T05:35:58.704366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588784 | REC_0007553 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 4.6 | 76 | female | 1 | 22 | 6 | 1 | pembrolizumab 200 mg q3w | 21.6 | false | MSS | 2026-03-15T05:35:58.704596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649666 | REC_0007554 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 10.2 | 71 | female | 1 | 16 | 5.3 | 2 | sotorasib 960 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:58.704884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652486 | REC_0007555 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 9.2 | 60 | male | 1 | 13 | 4.3 | 4 | osimertinib 80 mg daily | 8.8 | true | MSS | 2026-03-15T05:35:58.705121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120466 | REC_0007556 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 6 | 62 | female | 0 | 35 | 4.2 | 5 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:35:58.705352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124154 | REC_0007557 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 36 | 15.9 | 77 | female | 2 | 18 | 5.3 | 5 | alectinib 600 mg BID | 8.3 | true | MSS | 2026-03-15T05:35:58.705589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913372 | REC_0007558 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 8.7 | 57 | female | 1 | 16 | 5.5 | 8 | sotorasib 960 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:58.705820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357553 | REC_0007559 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 4.4 | 77 | female | 2 | 42 | 7.2 | 9 | carboplatin + paclitaxel + pembrolizumab | 11.2 | false | MSS | 2026-03-15T05:35:58.706051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254097 | REC_0007560 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.7 | 75 | female | 2 | 11 | 5 | 2 | pembrolizumab 200 mg q3w | 14.8 | false | MSS | 2026-03-15T05:35:58.706280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420829 | REC_0007561 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.8 | 70 | female | 2 | 68 | 4.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.3 | false | MSS | 2026-03-15T05:35:58.706513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321822 | REC_0007562 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 15.9 | 53 | male | 0 | 11 | 4.8 | 1 | alectinib 600 mg BID | 13.2 | true | MSS | 2026-03-15T05:35:58.706756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885247 | REC_0007563 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 28 | 5.3 | 59 | female | 1 | 74 | 4 | 0 | carboplatin + paclitaxel + pembrolizumab | 67.3 | false | MSS | 2026-03-15T05:35:58.706996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409500 | REC_0007564 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 14 | 2.5 | 75 | female | 2 | 11 | 6.5 | 1 | osimertinib 80 mg daily | 19.7 | true | MSS | 2026-03-15T05:35:58.707237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309962 | REC_0007565 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 6.5 | 78 | male | 1 | 39 | 5.5 | 2 | pembrolizumab 200 mg q3w | 17.8 | true | MSS | 2026-03-15T05:35:58.707483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179979 | REC_0007566 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.2 | 78 | female | 2 | 12 | 6.5 | 6 | entrectinib 600 mg daily | 13 | true | MSS | 2026-03-15T05:35:58.707733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659719 | REC_0007567 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 17.8 | 67 | female | 1 | 17 | 3.4 | 7 | alectinib 600 mg BID | 16.9 | false | MSS | 2026-03-15T05:35:58.708202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104607 | REC_0007568 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 7.2 | 69 | female | 1 | 22 | 5 | 1 | alectinib 600 mg BID | 17.7 | true | MSS | 2026-03-15T05:35:58.708495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130044 | REC_0007569 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.2 | 64 | male | 1 | 7 | 6.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.4 | false | MSS | 2026-03-15T05:35:58.708750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758081 | REC_0007570 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.9 | 60 | female | 0 | 20 | 5.9 | 6 | osimertinib 80 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:58.709005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930160 | REC_0007571 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 14.3 | 72 | female | 2 | 7 | 6.2 | 4 | osimertinib 80 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:35:58.709262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745276 | REC_0007572 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.9 | 87 | female | 1 | 6 | 8.2 | 5 | sotorasib 960 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:58.709523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302473 | REC_0007573 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 17 | 85 | female | 0 | 9 | 5.6 | 7 | osimertinib 80 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:58.709771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499643 | REC_0007574 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 20.5 | 59 | female | 0 | 10 | 6.1 | 7 | alectinib 600 mg BID | 8.3 | false | MSI-H | 2026-03-15T05:35:58.710014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117997 | REC_0007575 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 18 | 67 | female | 0 | 16 | 5.7 | 5 | alectinib 600 mg BID | 12.7 | true | MSI-H | 2026-03-15T05:35:58.710260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657499 | REC_0007576 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 6 | 68 | male | 1 | 44 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:35:58.710510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535868 | REC_0007577 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.4 | 71 | female | 1 | 53 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.5 | true | MSS | 2026-03-15T05:35:58.710757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421091 | REC_0007578 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.9 | 67 | female | 1 | 10 | 7.5 | 6 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:58.711007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141644 | REC_0007579 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 5.8 | 74 | female | 2 | 3 | 5.2 | 2 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:58.711255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310333 | REC_0007580 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 8.6 | 66 | female | 0 | 1 | 4.5 | 2 | alectinib 600 mg BID | 18.5 | true | MSS | 2026-03-15T05:35:58.711657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459871 | REC_0007581 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.4 | 75 | female | 2 | 16 | 7.1 | 4 | entrectinib 600 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:58.711922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683455 | REC_0007582 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 11.4 | 76 | female | 2 | 11 | 5.1 | 7 | osimertinib 80 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:35:58.712364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274707 | REC_0007583 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 34 | 5.2 | 59 | male | 1 | 13 | 3.6 | 1 | osimertinib 80 mg daily | 23.8 | false | MSS | 2026-03-15T05:35:58.712644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415565 | REC_0007584 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 17.6 | 81 | female | 2 | 10 | 8.3 | 6 | entrectinib 600 mg daily | 7.7 | false | MSI-H | 2026-03-15T05:35:58.712905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180947 | REC_0007585 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 17 | 14.2 | 61 | male | 0 | 25 | 5.4 | 4 | pembrolizumab 200 mg q3w | 13.5 | false | MSI-H | 2026-03-15T05:35:58.713155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949443 | REC_0007586 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 6.2 | 65 | female | 1 | 16 | 4.4 | 1 | pembrolizumab 200 mg q3w | 16.7 | false | MSS | 2026-03-15T05:35:58.713398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894912 | REC_0007587 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.5 | 60 | male | 0 | 6 | 6.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.9 | true | MSS | 2026-03-15T05:35:58.713644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345271 | REC_0007588 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 20.5 | 66 | female | 1 | 22 | 6.3 | 5 | alectinib 600 mg BID | 14.7 | true | MSS | 2026-03-15T05:35:58.713889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497841 | REC_0007589 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 20 | 12.6 | 76 | male | 1 | 22 | 5.5 | 0 | alectinib 600 mg BID | 39.1 | true | MSI-H | 2026-03-15T05:35:58.714137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518905 | REC_0007590 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 3.2 | 66 | male | 0 | 45 | 5.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:58.714382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952097 | REC_0007591 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 12 | 11.5 | 76 | female | 1 | 19 | 3 | 5 | alectinib 600 mg BID | 10.7 | false | MSI-H | 2026-03-15T05:35:58.714630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602426 | REC_0007592 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 5.2 | 64 | male | 1 | 8 | 6.2 | 5 | sotorasib 960 mg daily | 9 | false | MSS | 2026-03-15T05:35:58.714876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433449 | REC_0007593 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.9 | 90 | female | 1 | 14 | 5.7 | 5 | alectinib 600 mg BID | 9.5 | false | MSI-H | 2026-03-15T05:35:58.715254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354202 | REC_0007594 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 8.2 | 73 | female | 1 | 53 | 5.3 | 7 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:35:58.715506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876793 | REC_0007595 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 30 | 10.9 | 73 | male | 2 | 16 | 4.3 | 0 | alectinib 600 mg BID | 37.2 | false | MSS | 2026-03-15T05:35:58.715757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533881 | REC_0007596 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 6.3 | 70 | male | 2 | 14 | 4.4 | 1 | pembrolizumab 200 mg q3w | 23 | false | MSS | 2026-03-15T05:35:58.716007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238117 | REC_0007597 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 6.6 | 71 | female | 2 | 8 | 6 | 5 | sotorasib 960 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:58.716314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473701 | REC_0007598 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 10.6 | 76 | female | 3 | 16 | 7.8 | 2 | entrectinib 600 mg daily | 18.4 | false | MSI-H | 2026-03-15T05:35:58.716564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248997 | REC_0007599 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 12.2 | 72 | female | 2 | 8 | 5.9 | 0 | osimertinib 80 mg daily | 33.3 | false | MSS | 2026-03-15T05:35:58.716820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470110 | REC_0007600 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 14.4 | 65 | female | 0 | 12 | 6.6 | 2 | osimertinib 80 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:58.717072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.